Filing Flows › Fortress Biotech (FBIO) › Q1 2025
Fortress Biotech (FBIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Fortress Biotech (FBIO) reported revenue of $13.1M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -13% from the quarter before. Operating margin was -169.9%, net loss $24.7M (187.9% of revenue).
Fortress Biotech, Q1 2025: revenue $13.1M (+0.8% year over year), operating margin -169.9%, net loss $24.7M, operating cash flow −$19.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.1M | -13% | +0.8% |
| Operating profit | −$22.3M | — | — |
| Net earnings | −$24.7M | — | — |
| Operating cash flow | −$19.6M | — | — |
What changed
Revenue was $13.1M in Q1 2025, up 1% year over year and down 13% from the previous quarter. Qbrexza was the largest line at 39% of revenue. Amzeeq added $345K year over year (up 46%), 317% of the total change. Other / legacy product revenue declined 38%.
Operating costs exceeded revenue by $22.3M, an operating margin of -169.9%. Total costs fell 29% while revenue rose 1%. The fastest-growing cost line was SG&A (+43%). The quarter ended with a net loss of $24.7M, narrower than the previous quarter's $26.3M loss. Minority interests bore $14.1M of it: to shareholders the quarter was a loss of $10.6M.
Operating cash flow was −$19.6M. Non-cash charges added back $1.2M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items used $2.4M.
Questions
What was Fortress Biotech's revenue in the first quarter 2025?
Fortress Biotech (FBIO) reported revenue of $13.1M for the first quarter 2025 (Q1 2025), +0.8% from a year earlier and -13% from the quarter before.
Was Fortress Biotech profitable in the first quarter 2025?
Operating loss was $22.3M (-169.9% of revenue) and net loss $24.7M.
Source: Fortress Biotech 10-Q on SEC EDGAR.